At the recent ASCO GU conference, we learned the results from the ARAMUS phase III trial which evaluated Darolutamide, an androgen receptor (AR) antagonist (a drug that prevents androgens from affecting prostate and prostate cancer cells). The trial studied the efficacy and safety of darolutamide in men with nmCRPC men.
African American Men experience a survival advantage over Caucasian Men when they take either Zytiga or Xtandi.
Co-pay assistance is now available for advanced Prostate Cancer drugs.
Studies consistently show that most clinical trial participants want to know what the research communities learned from their participation, yet most never hear from the sponsor or research site staff at all after a clinical trial has concluded. A growing number of pharmaceutical, biotechnology, and medical device companies have recognized this situation and are closing the loop with their study volunteers by providing clinical trial results summaries, also known as lay language or plain language summaries.
You can participate on an editorial board that produces documents provided to clinical trial participants describing the trial and its results.
A preplanned early analysis of the Phase III TITAN trial shows that Erleada (apalutamide) has met the both of the trial’s primary endpoints in the treatment of men with metastatic castration-sensitive prostate cancer (CSPC).
The Food and Drug Administration (FDA) has approved a new Phase 1 clinical trial to evaluate ARV-110 for men with metastatic castration-resistant prostate cancer (mCRPC).
Reach out to the PAN Foundation to see if you qualify for economic support for your prostate cancer drugs.
Health Canada has recently approved an expanded use for enzalutamide (Xtandi) so that it can now be prescribed to treat men with non-metastatic castration-resistant prostate cancer (nmCRPC).
Sub-group analysis of the clinical trial ERA 223 signal that the concerns about the use in combination of Zytiga and Xofigo might not cause a significant increase in the risk for developing bone fractures if a man is also simultaneously on a bone targeted therapy.
Palliative care improves a person’d quality of life and it also can extend a person’s survival.
If you are an African American man and have been diagnosed with prostate cancer, you can help us better understand the significant differences that African American men have in risk factors for prostate cancer.
In a small, 25 man, but significant clinical trial of men with metastatic castrate-resistant prostate cancer (mCRPC) who also qualified for Radium-223 (Xofigo) it was shown that the level of pain a man has during the treatment could be used as a prognostic tool of his survival.
Use of a computerized brain exercise program designed to help people sharpen their cognitive function was found to be effective against chemo brain in breast Cancer Thrivers and will probably be useful for Cancer Thrivers with any chemo brain.
Get help with your drug co-pays
The 10-year outcomes from the RADAR phase 3 trial were recently published. The results showed that men with locally advanced prostate cancer who were treated with six months of androgen suppression therapy (ADT) and prostatic radiotherapy did not do as well as those who were treated with 18 months of ADT and radiation.
In an analysis of the NRG Oncology clinical trial NRG-RTOG 9202 it was shown that the interval of time to biochemical reoccurrence (PSA only or BCR), or the time it takes for previously treated prostate cancer to return as indicated by a prostate-specific antigen (PSA) rise, could be used as a surrogate endpoint for survival for men with locally advanced prostate cancer.
It was announced today that the Phase 3 ARCHES trial which evaluated XTANDI (enzalutamide) along with androgen deprivation therapy (ADT) in men with metastatic hormone-sensitive prostate cancer (mHSPC) met its primary endpoint, significantly improving radiographic progression-free survival (rPFS) versus ADT alone.
Prostate cancer treatments, particularly hormone therapy (ADT) can have a significant effect on speeding up the process of thinning and weakening the bones. There are some available treatments (Zoledronic acid aka Zoladex and denosumab aka Xgeva) which are designed to slow down or reverse this process; however, they are known to have many adverse side effects themselves. These side effects can include severe fractures of the femur which could limit survival and cataracts. For this reason, these treatments are usually used later, when men become castrate resistant and metastatic.
A recent finding shows that men with a Gleason score of 9–10 prostate cancer may derive a smaller survival benefit from androgen deprivation therapy (ADT) compared with those with Gleason score of 8.
According to Anthony V. D’Amico, MD, Ph.D., who is chief of the Division of Genitourinary Radiation Oncology and an institute physician at Dana-Farber Cancer Institute at Brigham and Women’s Hospital in Boston, “It makes logical sense that in these very aggressive prostate cancers, you need a multi-modality approach.”